Oxford BioTherapeutics announce agreement with Genmab to add further depth and momentum into its drug pipeline.
Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s … Continued
Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies and Kite, a Gilead Company, have announced that they have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five … Continued
Oxford BioTherapeutics (“OBT”) a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, announced that Boehringer Ingelheim (“BI”) has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled by OBT’s proprietary OGAP® target discovery platform. It is one of several assets that have … Continued
Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid tumours. Dose-escalation is the first part of the Phase I program that includes two U.S. … Continued